{
    "clinical_study": {
        "@rank": "16444", 
        "arm_group": [
            {
                "arm_group_label": "Inactive lozenge", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks"
            }, 
            {
                "arm_group_label": "Methylcobalamin", 
                "arm_group_type": "Experimental", 
                "description": "Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Vegetarians are known to be deficient in vitamin B12, due to a lack or absence of dietary\n      animal produce, which can elevate homocysteine. There is strong evidence indicating that\n      elevated plasma total homocysteine (tHcy) is a contributor to chronic conditions, such as\n      primary cardiovascular disease (CVD). The study hypothesis is: There will be a significant\n      decrease in plasma tHcy of vegetarians following the intervention by supplementary vitamin\n      B12 (of the methylcobalamin type) and this will lead to a reduction of the risk of CVD."
        }, 
        "brief_title": "Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians - Clinical Trial", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Vitamin B12 Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Vitamin B 12 Deficiency", 
                "Hyperhomocysteinemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Having a plasma tHcy >10 micromol/L\n\n          -  Not suffering from conditions as described in exclusion criteria.\n\n          -  Vegetarian for at least one year.\n\n          -  Not participating in a weight reducing diet.\n\n          -  Not consuming regularly vitamin B12 supplements.\n\n          -  Give written consent to participate in clinical trial and be fluent in English\n             language.\n\n        Exclusion Criteria:\n\n          -  Having a plasma tHcy less or equal to 10 micromol/L.\n\n          -  Suffering from pernicious anemia or other vitamin B12 deficiency disease.\n\n          -  Undergone bowel surgery or suffer from gastrointestinal disease.\n\n          -  Pregnant, lactating or trying to conceive.\n\n          -  Smoker.\n\n          -  Alcohol intake regularly greater than official recommended daily units (i.e. 2 units\n             female, 3 units male).\n\n          -  Consume large amounts of caffeine (regular consumption of >4 cups of strong tea or\n             coffee per day).\n\n          -  Use of medications known to influence nutritional status.\n\n          -  Have genetic metabolic disease.\n\n          -  Suffer from renal failure, diabetes, thyroid disease, cardiovascular disease,\n             dementia or cancer.\n\n          -  Have a known blood-borne infection (e.g. Hepatitis or HIV)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661309", 
            "org_study_id": "Methylcobalamin"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Inactive lozenge", 
                    "Methylcobalamin"
                ], 
                "description": "Manufactured to mimic 1mg methylcobalamin lozenge", 
                "intervention_name": "Inactive lozenge", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Inactive lozenge", 
                    "Methylcobalamin"
                ], 
                "description": "Aimed at reducing plasma tHcy.", 
                "intervention_name": "Methylcobalamin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Vitamin B12"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin B 12", 
                "Hydroxocobalamin", 
                "Vitamin B Complex", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hyperhomocysteinemia", 
            "Methylcobalamin", 
            "Cardiovascular disease", 
            "Plasma total homocysteine", 
            "Vegetarians"
        ], 
        "lastchanged_date": "May 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "state": "Middlesex", 
                    "zip": "TW8 9GA"
                }, 
                "name": "University of West London"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "To Critically Investigate and Evaluate Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians, Who May Have a Resultant Susceptibility to Hyperhomocysteinemia Related Diseases.", 
        "other_outcome": {
            "measure": "Improvement in body mass index", 
            "safety_issue": "No", 
            "time_frame": "16 weeks per participant"
        }, 
        "overall_official": [
            {
                "affiliation": "University of West London", 
                "last_name": "Amalia A Tsiami, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of West London", 
                "last_name": "David C Chappell, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Research Councils UK", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Reduction of plasma total homocysteine of vegetarians", 
            "safety_issue": "No", 
            "time_frame": "16 weeks per participant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661309"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of West London", 
            "investigator_full_name": "Derek Obersby", 
            "investigator_title": "PhD Student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Improvement in systolic and diastolic blood pressure", 
            "safety_issue": "No", 
            "time_frame": "16 weeks per participant"
        }, 
        "source": "University of West London", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of West London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}